Annovis Bio (ANVS) EBITDA (2019 - 2026)
Annovis Bio (ANVS) posted EBITDA of -$18.0 million for Q1 2026, down 85.45% sequentially from -$9.7 million in Q4 2025, and down 185.71% YoY from $21.0 million in Q1 2025.
Annovis Bio (ANVS) EBITDA (2019 - 2026) Analysis & Trends
Annovis Bio has reported EBITDA for 8 years, with the latest figure at -$18.0 million in Q1 2026.
- Quarterly EBITDA fell 185.71% year-over-year to -$18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.4 million (down 64.4% YoY) and the FY2025 annual result came in at -$29.7 million, down 11.22% from the prior year.
- EBITDA retreated to -$18.0 million in Q1 2026 per ANVS's latest filing, from -$9.7 million in the prior quarter.
- Over five years, EBITDA peaked at -$4.4 million in Q3 2024 and troughed at -$18.0 million in Q1 2026.
- A 5-year average of -$8.5 million and a median of -$7.8 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2024 and 2026: EBITDA jumped 70.48% in 2024, then slumped 185.71% in 2026.
- Over 5 years, EBITDA stood at -$7.8 million in 2022, then slumped by 33.87% to -$10.4 million in 2023, then surged by 35.46% to -$6.7 million in 2024, then slumped by 44.01% to -$9.7 million in 2025, then slumped by 85.45% to -$18.0 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$18.0 million, -$9.7 million, and -$7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | Annovis Bio | 66.60 Mn | 66.60 Mn | - | -14.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.00 Mn |
| Dec 31, 2025 | -9.71 Mn |
| Sep 30, 2025 | -7.43 Mn |
| Jun 30, 2025 | -6.27 Mn |
| Mar 31, 2025 | -6.30 Mn |
| Dec 31, 2024 | -6.74 Mn |
| Sep 30, 2024 | -4.39 Mn |
| Jun 30, 2024 | -7.76 Mn |
| Mar 31, 2024 | -7.80 Mn |
| Dec 31, 2023 | -10.44 Mn |
| Sep 30, 2023 | -14.86 Mn |
| Jun 30, 2023 | -9.76 Mn |
| Mar 31, 2023 | -9.97 Mn |
| Dec 31, 2022 | -7.80 Mn |
| Sep 30, 2022 | -6.48 Mn |
| Jun 30, 2022 | -5.97 Mn |
| Mar 31, 2022 | -5.25 Mn |
| Dec 31, 2021 | -5.92 Mn |
| Sep 30, 2021 | -2.85 Mn |
| Jun 30, 2021 | -2.53 Mn |